The University of Texas System

Joshua Engstrom

Keith P Johnston

Robert O Williams, Iii

Alan B Watts

Jasmine Rowe

Maria Andrea Mazuski

Miguel Angelo Rodrigues

Jasmine Tam

Robert O Williams Iii

Robert O Williams

Iii Robert O Williams

The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.

Templated open flocs of anisotropic particles for enhanced pulmonary delivery

Compositions and methods of making brittle-matrix particles through blister pack freezing

The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cmarea/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30&#xb0; C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm.

Formation of stable submicron peptide or protein particles by thin film freezing

The present invention also provides a high concentration low viscosity suspension of an pharmaceutically acceptable solvent with one or more sub-micron or micron-sized non-crystalline particles comprising one or more proteins or peptides. Optionally one or more additives in the pharmaceutically acceptable solvent to form a high concentration low viscosity suspension with a concentration of at least 20 mg/ml and a solution viscosity of between 2 and 100 centipoise that is suspendable upon shaking or agitation, wherein upon delivery the one or more sub-micron or micron-sized peptides dissolves and do not form peptide aggregates syringeable through a 21 to 27-gauge needle.

Low viscosity highly concentrated suspensions

Growing community of inventors

Spotswood, NJ, United States of America

Joshua Engstrom